ANTINEO

🎓 The essence of Antineo's expertise with resistant model is compiled in this application note. 📊 Key findings show that the maintenance of the whole tumor microenvironment is needed and critical for the acquisition of tumor resistance. Removing the tumor microenvironment induces a loss of the resistant phenotype. TME is therefore a very promising target for oncology drug developement.

As 2 famous mice would say : “What do you want to do tonight..? The same thing we do every night, try to take over the world!”, we ultimately come up with a plan of our own.   2026 Q3 & Q4 will be busy for me, as I will represent ANTINEO on 2 continents : Europe and North America. A world tour to present and discuss our preclinical oncology models (tumoroids, CDX, PDX), translational strategies and potential collaborations. 📍 Our 2026 Q3 & Q4 event agenda : - BioHorizon, Montreal, Canada | October 6-8 - Collaborative days, Lyon, France | October 13 - Bio Europe, Cologne, Germany | 9-11 November - BioFit, Marseille, France | 10-11 December If you're attending any of these events and would like to discuss, feel free to reach out: I'd be happy to connect ! A special thanks to MabDesign, Business France – Santé and France2030 for such opportunities.

Exactly one month ago, 2 equally important events took place: 1️⃣ the football World Cup had just started and ⚽ 2️⃣ our Study Director and head of business development Marie Tautou presented 🖥️ ANTINEO’s 3D bioprinted tumoroids during a webinar organized by AFSSI Sciences de la Vie. 🥅 While the objective of the first is to score as many goals as possible, our goal is to score as many drug candidates as possible to help our customers select the best drug candidate during their preclinical phases. Our in vitro tumoroids allow the re-creation of a tumor microenvironment, with a customized and controlled level of complexity, from 3D monoculture of cancer cells to 2 or 3-cell-type tumoroids (immune cells, cancer-associated fibroblasts and adipocytes). 🏆 In the same way, a football coach will select their players for their complementarity on the field, our expertise is to guide and advise on the best model selection (from in vitro to in vivo) for a successful preclinical package. With more than 200 models available (10-times more than a football squad), there is certainly a winning combination. 

🤩 Less than a month after joining, and already presenting :). We are also feeling a momentum and a deeper level of questionning by our customers on the most relevant model to be used during preclinical studies. That's precisely where our expertise is making the most sense, providing with state of the art advice, rooted in a decade of experience and hands-on, to provide themost robust preclinical package possible. 👏 And bravo Pierre Gaudriault for the quick catch-up with our in vitro results

🚨 Breaking news, we have a major addition to the team, quite literally, given his height. We are super happy to welcome Pierre Gaudriault in ANTINEO as head of growth development. 💪 At Antineo, we are convinced that complementarity between in vitro and in vivo models is a key success factor for a robust preclinical package and subsequent CTA/IND filing. 🤝 By combining Pierre’s nearly 10 years of experience with in vitro models (particularly organoids and tumoroids) with Antineo’s excellence in oncology in vivo models is a key milestone in becoming a “1-stop shop” oncology preclinical service company. 🚀In this period of market rebound, Pierre will also drive our lead acquisition and Business development activity of the company, in tandem with @marie tautou. As Pierre likes to say: “let’s keep it simple and fun” Welcome aboard Pierre

Zoom Sur 2️⃣ nouveaux projets de recherche en cancérologie du programme Preuve du Concept ! 🥳 🏆 À l’issue d’une nouvelle commission organisée en avril 2026, 2️⃣ projets accompagnés par le Cancéropôle Lyon Auvergne-Rhône-Alpes et Lyonbiopôle Auvergne-Rhône-Alpes ont été retenus pour bénéficier du soutien de la Région Auvergne-Rhône-Alpes dans le cadre du dispositif « Preuve du Concept ». 🔸Le projet Lung3DPrint : Des modèles cellulaires bio-imprimés 3D 3.0 pour mieux prédire l’efficacité des thérapies dans le cancer du poumon ! Porté par Michael Duruisseaux, CRCL Centre de Recherche en Cancérologie de Lyon en partenariat avec l'entreprise ANTINEO 🔸Le projet TRACERS,  Révolutionner le suivi des cancers métastatiques en observant la tumeur vivante dans le sang ! Porté par Arnaud Vigneron, CRCL Centre de Recherche en Cancérologie de Lyon en partenariat avec l'entreprise Sirius NeoSight 👏 Toutes nos félicitations aux lauréats ! Découvrez les projets en détail 🧷 https://lnkd.in/e_86_VJ6 Ces deux projets innovants à haute valeur ajoutée visent ainsi à démontrer la validité de leur Preuve du Concept, tout en contribuant au dynamisme et au développement économique du territoire grâce aux partenariat porté avec des entreprises régionales.

📍 June 22-25 at San Diego Antineo will be at BIO International Convention 2026 as part of the French delegation supported by Business France Healthcare - North America. Marie Tautou will be there to connect with biotech and pharma teams working on oncology drug development and discuss how our preclinical models can support their pipeline. Whether you're exploring PDX models, 3D in vitro assays, or acquired resistance models, we'd love to hear about your research. 🔬 Attending BIO US? Reach out to schedule a meeting. #services #choosefrance #frenchhealthcare #businessfrancenorthamerica #BIOUS2026 #oncology

📍 Retour sur l’AFSTAL 2026 Notre équipe était présente cette semaine au congrès AFSTAL à Reims ! Cette année, ce sont Doriane Mathé / Poloni, Clémence Grosjean et Pierre-Antoine et qui ont porté les couleurs de notre équipe sur le congrès. Une belle opportunité de rencontrer nos partenaires, d’échanger avec la communauté scientifique et de découvrir les dernières innovations du secteur. Merci à l’AFSTAL pour l’organisation de cette belle édition à Reims, ainsi qu’à toutes les personnes avec lesquelles ils ont eu le plaisir d’échanger. Nous espérons que chacun repart avec de nouvelles idées, de nouvelles perspectives et de belles rencontres en tête ! #AFSTAL #Reims #RecherchePréclinique #LifeSciences #Science #Innovation #Collaboration #CommunautéScientifique #Networking

📋 Case study : a biotech starts with 6 candidates. Same target, same indication. In 2D, four of them look promising. The team runs a screen in 3D bioprinted tumors before committing to in vivo studies. The results are humbling. Two of the "promising" candidates collapse completely in 3D : the spatial architecture of the tumor exposes a penetration issue that flat cultures had masked. One compound that looked average in 2D rises to the top. They enter in vivo studies with 2 candidates instead of 4. ⏱️ Time saved: ~4 months. 💰 Cost avoided: significant. 🎯 Signal quality: much sharper. This a pattern we see play out regularly. 3D screening doesn't just improve predictivity, it can change which questions you're asking and save you a lot of money and time. That shift alone can redefine the dynamic of a preclinical program. Has a model switch ever surprised you with unexpected results ? #Oncology #3DModels #Spheroids #DrugDiscovery #Biotech #PreclinicalResearch #CandidateScreening

2D cell cultures have driven drug discovery for decades but the industry is quietly moving on, and 3D models are leading the shift. Here's why it matters for your pipeline ↓ 🔬 Cells in a flat dish behave differently from cells in a tumor. They lack the spatial organization, the oxygen gradients, the cell-cell interactions that define how a real tumor responds to treatment. 3D models (spheroids, organoids, tumor-on-a-chip) restore that complexity. They're not perfect but they're considerably closer to biology. 🎯 What this means for candidate screening is better predictivity earlier in the pipeline. Compounds that look promising in 2D but fail in 3D are likely to fail in vivo, better to know at week 4 than at month 18. 3D models are becoming a powerful triage tool: surface the real candidates faster, cut the noise earlier. ⚡ The competitive edge for biotech with leaner pipelines and more confident go/no-go decisions. Also less money spent advancing candidates that shouldn't have made it past screening. In an industry where the cost of a late-stage failure can run into hundreds of millions, earlier predictivity isn't a nice-to-have, it's a strategic advantage. Of course 3D models won't replace in vivo studies. But they're reshaping when and how decisions get made. Are you already integrating 3D models into your screening pipeline ? We would love to discuss with you how our 3D bioprinted tumors can transform your preclinical package. #Oncology #3DModels #DrugDiscovery #Organoids #Biotech #PreclinicalResearch #TherapeuticPipeline